Merck's (MRK) tulisokibart met primary and key secondary endpoints in Phase 2b study in patients with moderate to severe hidradenitis suppurativa

Positive mid-stage readouts in immunology follow a familiar sequence: the Phase 2 hit de-risks the asset's mechanism in the indication but leaves the registration question open, and historically it is the Phase 3 design, endpoints and regulatory dialogue that determine whether the signal holds at larger scale. Hidradenitis suppurativa is a crowded and validated space, with multiple biologics already approved or in late development, so the commercial read depends less on efficacy alone than on differentiation against the incumbent class on dosing, durability and safety. The actor here is the US-listed Merck, not the German namesake, a distinction that has confused headline parsing before; the asset sits in its immunology pipeline rather than the dominant oncology franchise, so single-asset readouts of this kind have tended to move the equity modestly unless the data imply label or market-size expansion. Worth watching is the full dataset at a medical meeting, the durability of response off treatment, and any Phase 3 initiation language, since the step from Phase 2b to pivotal commitment is where pipelines of this kind are repriced. As a pipeline note rather than a financial event, the read is directional only.